ArticleEuropean radiology2020
The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams.
Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Can structured integration of BI-RADS criteria by a clinical decision rule reduce the number of unnecessary biopsies in BI-RADS 4 lesions? A systematic review and meta-analysis.European radiology · 2025Pooled it
- Economic evaluation of breast MRI in screening - a systematic review and basic approach to cost-effectiveness analyses.Frontiers in oncology · 2023Pooled it
- Combined diagnosis of multiparametric MRI-based deep learning models facilitates differentiating triple-negative breast cancer from fibroadenoma magnetic resonance BI-RADS 4 lesions.Journal of cancer research and clinical oncology · 2023Trial
- Reduction of biopsy rate in BI-RADS4 breast lesions: potential of an abbreviated advanced DWI protocol.European radiology · 2025Article
- The role of the Kaiser score system in uncertain malignant potential (B3) breast lesions: a pilot study.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Article
- Diagnostic Performance of Kaiser Score for Characterization of Breast Lesions on Modified Abbreviated Breast MRI and Comparison with Full-Protocol Breast MRI.Journal of clinical medicine · 2025Article
- External validation of multiparametric magnetic resonance imaging-based decision rules for characterizing breast lesions and comparison to Kaiser score and breast imaging reporting and data system (BI-RADS) category.Quantitative imaging in medicine and surgery · 2025Article
- Reliability of Kaiser Score in Assessing Additional Breast Lesions Identified on Staging MRI in Patients with Breast Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Application of the Kaiser score on contrast-enhanced mammography in the differential diagnosis of breast lesions: comparison with breast magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2024Article
- Diagnostic accuracy of the breast MRI Kaiser score in suspected architectural distortions and its comparison with mammography.Scientific reports · 2024Article
- Quantitative evaluation of Kaiser score in diagnosing breast dynamic contrast-enhanced magnetic resonance imaging for patients with high-grade background parenchymal enhancement.Quantitative imaging in medicine and surgery · 2023Article
- Deep learning for predicting future lesion emergence in high-risk breast MRI screening: a feasibility study.European radiology experimental · 2023Article
- Diagnostic value of Kaiser score combined with breast vascular assessment from breast MRI for the characterization of breast lesions.Frontiers in oncology · 2023Article
- Combination of ultrafast dynamic contrast-enhanced MRI-based radiomics and artificial neural network in assessing BI-RADS 4 breast lesions: Potential to avoid unnecessary biopsies.Frontiers in oncology · 2023Article
- Breast MRI: does a clinical decision algorithm outweigh reader experience?European radiology · 2022Article
- Assessment of breast lesions by the Kaiser score for differential diagnosis on MRI: the added value of ADC and machine learning modeling.European radiology · 2022Article
- Can DWI provide additional value to Kaiser score in evaluation of breast lesions.European radiology · 2022Article
- Evaluation of the differentiation of benign and malignant breast lesions using synthetic relaxometry and the Kaiser score.Frontiers in oncology · 2022Article
- Magnetic resonance imaging in diagnosis of indeterminate breast (BIRADS 3 & 4A) in a general population.Insights into imaging · 2021Article
- [Artificial intelligence in breast imaging : Areas of application from a clinical perspective].Der Radiologe · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMRI is an integral part of breast cancer screening in high-risk patients. We investigated whether the application of the Kaiser score, a clinical decision-support tool, may be used to exclude malignancy in contrast-enhancing lesions classified as BI-RADS 4 on breast MRI screening exams.
methodsThis retrospective study included 183 consecutive, histologically proven, suspicious (MR BI-RADS 4) lesions detected within our local high-risk screening program. All lesions were evaluated according to the Kaiser score for breast MRI by three readers blinded to the final histopathological diagnosis. The Kaiser score ranges from 1 (lowest, cancer very unlikely) to 11 (highest, cancer very likely) and reflects increasing probabilities of malignancy, with scores greater than 4 requiring biopsy. Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic accuracy.
resultsThere were 142 benign and 41 malignant lesions, diagnosed in 159 patients (mean age, 43.6 years). Median Kaiser scores ranged between 2 and 5 in benign and 7 and 8 in malignant lesions. For all lesions, the Kaiser score's accuracy, represented by the area under the curve (AUC), ranged between 86.5 and 90.2. The sensitivity of the Kaiser score was high, between 95.1 and 97.6% for all lesions, and was best in mass lesions. Application of the Kaiser score threshold for malignancy (≤ 4) could have potentially avoided 64 (45.1%) to 103 (72.5%) unnecessary biopsies in 142 benign lesions previously classified as BI-RADS 4.
conclusionsThe use of Kaiser score in high-risk MRI screening reliably excludes malignancy in more than 45% of contrast-enhancing lesions classified as BI-RADS 4. KEY POINTS: • The Kaiser score shows high diagnostic accuracy in identifying malignancy in contrast-enhancing lesions in patients undergoing high-risk screening for breast cancer. • The application of the Kaiser score may avoid > 45% of unnecessary breast biopsies in high-risk patients. • The Kaiser score aids decision-making in high-risk breast cancer MRI screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.